Positive Results for DNA-based vaccine in humans
PowderMed, Ltd. announced the publication of positive results from a Phase I study evaluating its proprietary prophylactic DNA influenza vaccine in the journal Vaccine (volume 24, issue 21). Based on these results, PowderMed will start phase II studies using both annual and bird flu strains later this year.
Authored by lead researcher Dr. Hansi Dean, the report documents the safety and immunogenicity of PowderMed's monovalent influenza DNA vaccine delivered with the company's Particle Medicated Epidermal Delivery (PMED) needle-free injection system. The trial examined three doses of a DNA plasmid encoding the H3 haemagglutinin (HA) gene for Panama flu (1, 2 and 4 micrograms) administered as a single dose to 36 healthy adult volunteers. Immune response was assessed according to criteria set by the Committee for Proprietary Medicinal Products (CPMP) for the approval of annual flu vaccines in the European Union.
At the maximum dose tested (4 micrograms), all subjects achieved a seroprotective level of antibodies demonstrating that this DNA vaccine is a viable candidate for expanded clinical evaluation as a potentially powerful defense against influenza and pandemic flu. The maximum dose (4 micrograms) passed the CPMP criteria at 21 days and was well tolerated. All three doses passed the CPMP criteria at 56 days.
"Recent years have seen a number of new influenza vaccine approaches tested in animal model systems and in the clinic. However, this study is the first successful demonstration of immunogenicity of an influenza DNA vaccine in humans," said Dr. Hansi Dean, now with the International AIDS Vaccine Initiative.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents

Aphids balance their diets by rebuilding plant amino acids

Bacterial protein could help find materials for your next smartphone
Domainex Secures £1.4m Biomedical Catalyst Award

Organs-on-chips for large-scale drug screening
VASTox prepares to commence next phase of clinical development for two neuro-disorder drug programmes
Cold-blooded
OncoMethylome Sciences Changes its Name to MDxHealth

Squeezing low-cost electricity from sustainable biomaterial
Cowpea_Chlorotic_Mottle_Virus
